Autoresearch: BIOSECURE CDMO realized pricing still unresolved (seventh day)
Seventh consecutive day: still no independent 2026 realized mAb fill-finish price series to reconcile −15% (2023–2025, Mordor) vs asserted Western CDMO pricing power. Consultant blogs (Vision Life Sciences, BioMed Nexus, Corstrate) forecast 5–10% or 10–20% rate increases; they are not a measured series. OMB BCOC list still 2026-12-18; FAR-clock ~3 years. Do not silently downgrade.
Autoresearch: BIOSECURE CDMO realized pricing still unresolved (seventh day)
Generated by
/autoresearchon 2026-08-24. Step-1 / bucket #8 healthcare gap-fill on biosecure-cdmo-scarcity-to-western-cdmo-pricing-power. Compact one-round scan. Priors skipped (headless). Context: vault/projects/stock-market.
Summary
The contradiction is still open. Do not silently downgrade. The 08-17 ingest recorded a −15% realized 2023–2025 mAb fill-finish price series (Mordor Intelligence) against this chain's Step 3 "pricing power" assertion. The 08-19 pass found no new 2026 realized series and dated the enforcement clock (OMB BCOC list 2026-12-18; FAR teeth ~3 years). This pass, 60 hours after Friday's dispatch, still finds no independent 2026 realized fill-finish or CDMO spot/contract price print.
What is new is more consultant forecast language, which is the wrong kind of evidence for this contradiction:
- Vision Life Sciences: "CDMO rates are expected to rise 5-10% annually as capacity tightens"; lock in partnerships "before the OMB list is published in late 2026"; U.S. manufacturing "unprepared." Restates the 79% / $10–20B / Catalent-to-Novo facts already on the wiki. Vendor with a reshoring-advisory incentive.
- BioMed Nexus "2026 Playbook": "10–20% price increases" 2026–2028, 2–3 year waitlists, TMO $1–2B diverted. No primary price table.
- Corstrate: "5 to 10% annually"; "federal enforcement not expected before late 2028" but "commercial market is not waiting." Circular with Vision.
None of these is a measured 2026 realized mAb / sterile-injectable / peptide fill-finish series. The 08-17 three-point adjudication list still stands: (1) does the −15% cover the BIOSECURE-removed segment; (2) Mordor's deflationary half is the credible half because of vendor incentive — the new blogs have the opposite incentive; (3) dated removal vs pricing-power-now.
Conviction and status unchanged. Human call, seventh consecutive day. OMB BCOC list 2026-12-18 remains the next dated clock.
Findings
| Claim | Status this pass | Why it doesn't close the contradiction |
|---|---|---|
| −15% mAb fill-finish 2023–2025 (Mordor) | Still the only measured series | Already on the mechanism page |
| OMB BCOC list by 2026-12-18 | Unchanged | Dated clock, not a price |
| WuXi AppTec on DoD 1260H (2026-06-08); WuXi Biologics not | Unchanged | Already ingested 08-19 |
| "5–10% / 10–20% expected CDMO rate increases" | New language, consultant blogs | Forecast, not realized; growth-framing incentive |
| TMO as named beneficiary | Restated (Casper / JPM HC) | Already Step 4 partial |
What this means
- biosecure-cdmo-scarcity-to-western-cdmo-pricing-power — no conviction or status change. Step 3 stays
partial. The consultant-forecast pile is the same class of claim as the original Alira/PharmaSource "pricing power" language, not an independent measured series. - Thin-vertical steer honored: this is the healthcare pass. No net-new chain.
Provenance
- Vision Life Sciences, BIOSECURE 2026 — CDMO advisory; 5–10% expected; OMB late-2026.
- BioMed Nexus playbook — 10–20% forecast; not a price series.
- Corstrate — restates Vision; late-2028 federal enforcement.
- Prior: 2026-08-17-autoresearch-gpo-contracts-drug-shortage-allocation-vs-price, 2026-08-19-autoresearch-biosecure-cdmo-realized-pricing-still-unresolved.
Open questions (unchanged)
- Is there a 2026 realized fill-finish / peptide CDMO price series from a non-vendor source (FDA, CMS, 10-Q segment, or a named sponsor's COGS commentary)?
- Does TMO's pharma-services segment print mix/price in Q3 that isolates BIOSECURE?